CVE-2023-6926

Improper Neutralization of Special Elements used in an OS Command ('OS Command Injection') in Crestron AM-300

Description

There is an OS command injection vulnerability in Crestron AM-300 firmware version 1.4499.00018 which may enable a user of a limited-access SSH session to escalate their privileges to root-level access.

Remediation

Solution:

  • Crestron has resolved this vulnerability in firmware version 1.4499.00023.001 or higher. Please see https://security.crestron.com https://security.crestron.com/  or contact True Blue Support for additional information.

Category

8.4
CVSS
Severity: High
CVSS 3.1 •
EPSS 0.13%
Third-Party Advisory cisa.gov
Affected: Crestron AM-300
Published at:
Updated at:

References

Link Tags
https://www.cisa.gov/news-events/ics-advisories/icsa-24-023-02 government resource third party advisory us government resource

Frequently Asked Questions

What is the severity of CVE-2023-6926?
CVE-2023-6926 has been scored as a high severity vulnerability.
How to fix CVE-2023-6926?
To fix CVE-2023-6926: Crestron has resolved this vulnerability in firmware version 1.4499.00023.001 or higher. Please see https://security.crestron.com https://security.crestron.com/  or contact True Blue Support for additional information.
Is CVE-2023-6926 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2023-6926 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2023-6926?
CVE-2023-6926 affects Crestron AM-300.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.